Market Briefing

Plans for U.S. tariffs on Gx

Fresenius is well positioned to navigate the evolving tariff environment, supported by limited exposure, significant U.S. manufacturing capacity, and a long-standing commitment to local production.

U.S. President Donald Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

According to the announcement of U.S. President Donald Trump last night, generic drugs imported into the United States would face zero tariffs for two years starting August 1, followed by a 100% tariff in August 2028 and a 200% tariff from August 2029. The phased approach is intended to encourage pharmaceutical manufacturers to shift production to the United States.

Fresenius is well positioned with strong U.S. domestic production

Fresenius is well positioned to navigate the evolving tariff environment. **Around 90% of our Group revenues are not exposed to U.S. tariffs**, supported by our strong European hospital business. At the same time, we have spent years building a substantial local presence in the United States through our "More in America" manufacturing and supply initiative. Today, we **produce around 70% of the medicines we sell in the U.S. domestically**, including sourcing a significant proportion of high-value active pharmaceutical ingredients locally.

This **local-for-local approach is a key element of our long-term manufacturing strategy** and a meaningful differentiator versus many competitors. Our U.S. footprint includes **more than 4,000 employees** and **nearly $1 billion invested in manufacturing** and logistics infrastructure in recent years. As a supplier of essential medicines and healthcare products, our focus is on maintaining resilient supply chains and ensuring reliable patient access.

Looking ahead, **the U.S. remains a strategically important market** for Fresenius. We **plan to continue investing in our manufacturing** and supply capabilities over the next five years and further strengthen our local presence. While we are not immune to tariffs, we believe our diversified business model, strong domestic manufacturing base, and **long-term commitment to the U.S. market** position us well to navigate the evolving trade environment.